Every year in Wales, more than 2500 men are diagnosed with prostate cancer and around 600 men die from the disease.
Scanning with mpMRI is the first-line test for prostate cancer. These scans can be difficult to interpret, with nearly 45% patients without prostate cancer receiving a false positive scan, and subsequent unnecessary biopsies with side effects. Solutions are needed to ensure patients don't receive unnecessary interventions, and diagnostic capacity is used effectively.
JivaRDX is a diagnostic aid for suspected prostate cancer scans that promptly highlights the existence of tumours. The tool has the potential to enable radiologists to make more informed decisions faster.
In this work, Prof Chris Hopkins and Mr Sohail Moosa, working with TriTech Institute, Hywel Dda University Health Board and Jiva.ai, demonstrated the first innovative deployments of JivaRDX within NHS Wales. Working with a real-world dataset of scans taken of patients in Hywel Dda, they demonstrated that JivaRDX alone has comparable accuracy to a radiologist. Staff satisfaction with the tool was also extremely high, and a parallel analysis showed that JivaRDX could be cost-effective within the prostate cancer pathway.
The next steps for Prof. Hopkins and the team will be to implement JivaRDX as a tool for radiologists in the live diagnosis of patients.
At Moondance, we are proud to have supported a platform that could reduce misdiagnosis, and unnecessary treatment costs and complications, whilst creating better outcomes for patients in Wales.
Download the full project evaluation below: